AP source: Johnson & Johnson agrees to pay $2.2B over Risperdal, Invega, Natreco

WASHINGTON - A federal law enforcement official says Johnson & Johnson and its subsidiaries have agreed to pay over $2.2 billion to resolve criminal and civil allegations of promoting three prescription drugs for off-label uses not approved by the Food and Drug Administration.

The official also says the allegations include paying kickbacks to physicians and pharmacies to recommend and prescribe Risperdal and Invega, both antipsychotic drugs, and Natrecor, which is used to treat heart failure.

The official spoke on condition of anonymity because the source was not authorized to speak publicly about the matter.

Print this article Back to Top